Shire Plc American Depositary Shares (SHPG) 258.02 $SHPG
Global Essential Thrombocythemia Therapeutics Pipeline Review 2014 - 10 Drug Profiles from 9 Companies
M2 - Thu Sep 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fshlvt/essential) has announced the addition of the "Essential Thrombocythemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Shire Plc - Incyte Corporation - Galena Biopharma, Inc. - Italfarmaco S.p.A. - Promedior, Inc. - Onconova Therapeutics, Inc. - Pharma Mar, S.A. Drug Profiles - anagrelide hydrochloride - ruxolitinib phosphate - PRM-151 - plitidepsin - givinostat - gandotinib - anagrelide hydrochloride CR - AZD-1480 - rigosertib sodium - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fshlvt/essential
Global Binge Eating Disorder Therapeutics Pipeline Review, H2 2014 Report - 5 Companies & 5 Drug Profiles
M2 - Wed Sep 10, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6jpp4g/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Teva Pharmaceutical Industries Limited - Shire Plc - Omeros Corporation - Heptares Therapeutics Ltd. - Lightlake Therapeutics Inc. Drug Profiles - armodafinil - lisdexamfetamine dimesylate - LT-12 - OMS-527 - Small Molecule Targeting Orexin 1 For more information visit http://www.researchandmarkets.com/research/6j...nge_eating
Kidney Transplantation Therapeutic Pipeline Review, H2 2014 - 29 Drug Profiles From 18 Companies
M2 - Tue Sep 09, 6:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqfkc/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Pharming Group N.V. - Grifols, S.A. - Novartis AG - Astellas Pharma Inc. - Shire Plc - Veloxis Pharmaceuticals A/S - La Jolla Pharmaceutical Company - Hansa Medical AB - Digna Biotech, S.L. - Viron Therapeutics, Inc. - Opsona Therapeutics Ltd. - Angion Biomedica Corp. - NovImmune SA - Tolera Therapeutics, Inc. - Bio-inRen Drug Profiles - tacrolimus ER - voclosporin - eculizumab - ASKP-1240 - belimumab - foralumab - cardiotrophin-1 - C1 esterase inhibitor (human) - BB-3 - QPI-1002 - TOL-101 - OPN-305 - IgG-Degrading Enzyme of Streptococcus pyogenes - FCR-001 - Immucellgram - C1 esterase inhibitor (human) - CFZ-533 - VT-111a - VT-214 - C1 esterase inhibitor (recombinant) - LJPC-101 - AS-2521780 - FFP-106 - ETR-002 - Cell Therapy for Kidney Transplantation - T-Cell Therapy for Kidney Transplant - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - BRN-1889 - albumin (human) For more information visit http://www.researchandmarkets.com/research/2mqfkc/kidney
Treasury Secretary's Upcoming Inversion Talk to Widen Spreads
at The Street - Fri Sep 05, 8:21AM CDT
The Treasury Secretary Jack Lew is expected to opine on tax inversions next week, a subject that has been a major issue for risk arbitrage spreads.
Upcoming Conferences, Dividends, Regulatory Disclosures, and Acquisitions - Research Reports on Medtronic, Humana, Shire, Biogen and Covidien
PR Newswire - Fri Sep 05, 8:05AM CDT
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Humana Inc. (NYSE: HUM), Shire Plc (NASDAQ: SHPG), Biogen Idec Inc. (NASDAQ: BIIB) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6245-100free.
Will AbbVie's $805 Million Agreement for Duvelisib Pay Off? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 4:10PM CDT
In order to boost its pipeline, AbbVie (ABBV) inked a collaboration agreement with Infinity Pharmaceuticals (INFI).
10 Stocks Billionaire John Paulson Loves in 2014
at The Street - Thu Sep 04, 8:33AM CDT
Here's a look at 10 stocks that Paulson & Co. bought in the most recently reported quarter.
Elections for Interim Dividend in Respect of the Six Months to June 30, 2014
M2 - Mon Sep 01, 9:16AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) announced on July 18, 2014 an interim dividend of 3.83 US cents per Ordinary Share payable on October 3, 2014 to shareholders on the register of members at the close of business on September 5, 2014.
Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 4:00PM CDT
Protalix (PLX) and Pfizer (PFE) announced that the FDA has approved Elelyso injection for pediatric patients suffering from type I Gaucher disease.
Critical Alerts For GoPro, Shire, Micron, Cisco Systems and Facebook Released By InvestorsObserver
PR Newswire - Fri Aug 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, SHPG, MU, CSCO and FB.
Is It Time to Buy AbbVie Stock?
Keith Speights, The Motley Fool - Motley Fool - Wed Aug 27, 9:45AM CDT
One month after two big announcements, the dust has settled somewhat for AbbVie . Those major announcements, of course, were a blow-out second quarter and the acquisition of Shire plc . In the first few days after the news hit the street,...
ViroPharma Incorporated - Consolidated Financial Statements
M2 - Fri Aug 22, 8:45AM CDT
Shire plc (the "Company"
(LSE: SHP, NASDAQ: SHPG) is today publishing the audited consolidated financial statements for ViroPharma Incorporated, dated April 29, 2014, for the year ending December 31, 2013.
Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:55PM CDT
Amicus Therapeutics (FOLD) announced positive data from its second phase III study on migalastat.
Global Lysosomal Storage Diseases Market 2014-2018: Key Vendors are Actelion Pharmaceuticals, BioMarin Pharmaceutical, Genzyme & Shire
M2 - Thu Aug 21, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9x5qt8/global_lysosomal) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. The Global Lysosomal Storage Diseases market will grow at a CAGR of 10.01 percent over the period 2013-2018. One of the prominent trends in this market is an increase in awareness among regulatory authorities. Regulatory bodies are steadily working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area. According to the report, special Provisions for orphan diseases (also known as rare diseases) such as lysosomal storage diseases is one of the major drivers. Special incentives in the form of funding, guidance, and market exclusivity offer an attractive opportunity to vendors for conducting research in this area. Further, the report states that one of the main challenges that the market faces is the limited patient population. The availability of a limited treatment group may prolong the time period by which a vendor could recover the Research & Development (R&D) expenses of the drug. Restricted patient population might also hinder effective evaluation of drugs based on clinical trials. To calculate the market size, the report considers revenue from the sales of various drugs available in the market for the management of different types of lysosomal storage diseases. These include: - Gaucher disease - Fabry disease - Mucopolysaccharidosis - Pompe disease - Cystinosis - NPC Key Vendors - Actelion Pharmaceuticals Ltd. - BioMarin Pharmaceutical Inc. - Genzyme Corp. - Shire plc Other Prominent Vendors - Mylan - Pfizer - Protalix - Raptor - Recordati - Sigma-Tau For more information visit http://www.researchandmarkets.com/research/9x..._lysosomal
Sanofi's (SNY) Cerdelga FDA Approved for Gaucher Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:30PM CDT
Sanofi (SNY) announced that the FDA has approved Cerdelga for the treatment of Gaucher disease type 1.
Alcobra Starts Patient Enrollment for Mid-Stage Study on MDX - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:21PM CDT
Alcobra (ADHD) announced that it has started patient enrolment in a phase IIb study on MDX.
Supernus's SPN-810 Gets Fast Track Status for ADHD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:30PM CDT
Supernus Pharmaceuticals, Inc.'s (SUPN) attention deficit hyperactivity disorder (ADHD) candidate, SPN-810 has received Fast track status in the U.S.
Critical Alerts For Shire, SouFun, Priceline, Halliburton and Verisk Analytics Released By InvestorsObserver
PR Newswire - Tue Aug 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SHPG, SFUN, PCLN, HAL and VRSK.
3 Health Care Stocks Nudging The Sector Higher
at The Street - Mon Aug 11, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
Global Essential Thrombocythemia Therapeutics Pipeline Review 2014 - 10 Drug Profiles from 9 Companies
M2 - Thu Sep 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fshlvt/essential) has announced the addition of the "Essential Thrombocythemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Shire Plc - Incyte Corporation - Galena Biopharma, Inc. - Italfarmaco S.p.A. - Promedior, Inc. - Onconova Therapeutics, Inc. - Pharma Mar, S.A. Drug Profiles - anagrelide hydrochloride - ruxolitinib phosphate - PRM-151 - plitidepsin - givinostat - gandotinib - anagrelide hydrochloride CR - AZD-1480 - rigosertib sodium - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fshlvt/essential
Global Binge Eating Disorder Therapeutics Pipeline Review, H2 2014 Report - 5 Companies & 5 Drug Profiles
M2 - Wed Sep 10, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6jpp4g/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Teva Pharmaceutical Industries Limited - Shire Plc - Omeros Corporation - Heptares Therapeutics Ltd. - Lightlake Therapeutics Inc. Drug Profiles - armodafinil - lisdexamfetamine dimesylate - LT-12 - OMS-527 - Small Molecule Targeting Orexin 1 For more information visit http://www.researchandmarkets.com/research/6j...nge_eating
Kidney Transplantation Therapeutic Pipeline Review, H2 2014 - 29 Drug Profiles From 18 Companies
M2 - Tue Sep 09, 6:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqfkc/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Pharming Group N.V. - Grifols, S.A. - Novartis AG - Astellas Pharma Inc. - Shire Plc - Veloxis Pharmaceuticals A/S - La Jolla Pharmaceutical Company - Hansa Medical AB - Digna Biotech, S.L. - Viron Therapeutics, Inc. - Opsona Therapeutics Ltd. - Angion Biomedica Corp. - NovImmune SA - Tolera Therapeutics, Inc. - Bio-inRen Drug Profiles - tacrolimus ER - voclosporin - eculizumab - ASKP-1240 - belimumab - foralumab - cardiotrophin-1 - C1 esterase inhibitor (human) - BB-3 - QPI-1002 - TOL-101 - OPN-305 - IgG-Degrading Enzyme of Streptococcus pyogenes - FCR-001 - Immucellgram - C1 esterase inhibitor (human) - CFZ-533 - VT-111a - VT-214 - C1 esterase inhibitor (recombinant) - LJPC-101 - AS-2521780 - FFP-106 - ETR-002 - Cell Therapy for Kidney Transplantation - T-Cell Therapy for Kidney Transplant - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - BRN-1889 - albumin (human) For more information visit http://www.researchandmarkets.com/research/2mqfkc/kidney
Treasury Secretary's Upcoming Inversion Talk to Widen Spreads
at The Street - Fri Sep 05, 8:21AM CDT
The Treasury Secretary Jack Lew is expected to opine on tax inversions next week, a subject that has been a major issue for risk arbitrage spreads.
Upcoming Conferences, Dividends, Regulatory Disclosures, and Acquisitions - Research Reports on Medtronic, Humana, Shire, Biogen and Covidien
PR Newswire - Fri Sep 05, 8:05AM CDT
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Humana Inc. (NYSE: HUM), Shire Plc (NASDAQ: SHPG), Biogen Idec Inc. (NASDAQ: BIIB) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6245-100free.
Will AbbVie's $805 Million Agreement for Duvelisib Pay Off? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 4:10PM CDT
In order to boost its pipeline, AbbVie (ABBV) inked a collaboration agreement with Infinity Pharmaceuticals (INFI).
10 Stocks Billionaire John Paulson Loves in 2014
at The Street - Thu Sep 04, 8:33AM CDT
Here's a look at 10 stocks that Paulson & Co. bought in the most recently reported quarter.
Elections for Interim Dividend in Respect of the Six Months to June 30, 2014
M2 - Mon Sep 01, 9:16AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) announced on July 18, 2014 an interim dividend of 3.83 US cents per Ordinary Share payable on October 3, 2014 to shareholders on the register of members at the close of business on September 5, 2014.
Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 4:00PM CDT
Protalix (PLX) and Pfizer (PFE) announced that the FDA has approved Elelyso injection for pediatric patients suffering from type I Gaucher disease.
Critical Alerts For GoPro, Shire, Micron, Cisco Systems and Facebook Released By InvestorsObserver
PR Newswire - Fri Aug 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, SHPG, MU, CSCO and FB.
Is It Time to Buy AbbVie Stock?
Keith Speights, The Motley Fool - Motley Fool - Wed Aug 27, 9:45AM CDT
One month after two big announcements, the dust has settled somewhat for AbbVie . Those major announcements, of course, were a blow-out second quarter and the acquisition of Shire plc . In the first few days after the news hit the street,...
ViroPharma Incorporated - Consolidated Financial Statements
M2 - Fri Aug 22, 8:45AM CDT
Shire plc (the "Company"
(LSE: SHP, NASDAQ: SHPG) is today publishing the audited consolidated financial statements for ViroPharma Incorporated, dated April 29, 2014, for the year ending December 31, 2013. Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:55PM CDT
Amicus Therapeutics (FOLD) announced positive data from its second phase III study on migalastat.
Global Lysosomal Storage Diseases Market 2014-2018: Key Vendors are Actelion Pharmaceuticals, BioMarin Pharmaceutical, Genzyme & Shire
M2 - Thu Aug 21, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9x5qt8/global_lysosomal) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. The Global Lysosomal Storage Diseases market will grow at a CAGR of 10.01 percent over the period 2013-2018. One of the prominent trends in this market is an increase in awareness among regulatory authorities. Regulatory bodies are steadily working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area. According to the report, special Provisions for orphan diseases (also known as rare diseases) such as lysosomal storage diseases is one of the major drivers. Special incentives in the form of funding, guidance, and market exclusivity offer an attractive opportunity to vendors for conducting research in this area. Further, the report states that one of the main challenges that the market faces is the limited patient population. The availability of a limited treatment group may prolong the time period by which a vendor could recover the Research & Development (R&D) expenses of the drug. Restricted patient population might also hinder effective evaluation of drugs based on clinical trials. To calculate the market size, the report considers revenue from the sales of various drugs available in the market for the management of different types of lysosomal storage diseases. These include: - Gaucher disease - Fabry disease - Mucopolysaccharidosis - Pompe disease - Cystinosis - NPC Key Vendors - Actelion Pharmaceuticals Ltd. - BioMarin Pharmaceutical Inc. - Genzyme Corp. - Shire plc Other Prominent Vendors - Mylan - Pfizer - Protalix - Raptor - Recordati - Sigma-Tau For more information visit http://www.researchandmarkets.com/research/9x..._lysosomal
Sanofi's (SNY) Cerdelga FDA Approved for Gaucher Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:30PM CDT
Sanofi (SNY) announced that the FDA has approved Cerdelga for the treatment of Gaucher disease type 1.
Alcobra Starts Patient Enrollment for Mid-Stage Study on MDX - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:21PM CDT
Alcobra (ADHD) announced that it has started patient enrolment in a phase IIb study on MDX.
Supernus's SPN-810 Gets Fast Track Status for ADHD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:30PM CDT
Supernus Pharmaceuticals, Inc.'s (SUPN) attention deficit hyperactivity disorder (ADHD) candidate, SPN-810 has received Fast track status in the U.S.
Critical Alerts For Shire, SouFun, Priceline, Halliburton and Verisk Analytics Released By InvestorsObserver
PR Newswire - Tue Aug 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SHPG, SFUN, PCLN, HAL and VRSK.
3 Health Care Stocks Nudging The Sector Higher
at The Street - Mon Aug 11, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
